MTVA - MetaVia Inc. Market Capitalization-to-Revenue Ratio
MetaVia Inc specializes in neural connection therapy for Alzheimer's disease. The market capitalization-to-revenue ratio reflects current price action, where the mark captures this metric. The company is pursuing expansion into the obesity and MASH treatment segments, yet the absence of commercial sales deprives it of pricing power until regulatory approval of its drugs.
Metric breakdowns and analytics for MetaVia Inc (MTVA)
- stock value and consensus price forecast:
- market capitalization statistics:
- book capitalization indicators:
- debt obligations and liquidity statistics:
- net income and valuation ratios data:
MTVA - Company Net Income|Net Profit Forecast MetaVia Inc|MTVA - P/E Multiple|Projected Price to Earnings Ratio metaviatx.com|MTVA - Price/Earnings to Growth Multiple|EV/EBITDA Multiple MetaVia Inc|MTVA - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year MetaVia|MTVA - Earnings per share for the last twelve months|Earnings per share growth in annualized terms for the last twelve months metaviatx.com|MTVA - Earnings per share growth in current year|Expected earnings per share growth for next year MetaVia Inc
- total revenue and sales volume data:
Summary company analytics:MetaVia Inc.
The use of CDMO contractors in the US minimizes capital expenditures for MetaVia Inc (MTVA), shifting the focus toward revenue efficiency. This multiplier compares market capitalization with daily sales volume, neutralizing distortions found in quarterly reporting. Such granularity allows investors to accurately assess the impact of operational risks on business valuation. The company's P/S dynamics clearly demonstrate the extent of asset overvaluation relative to actual cash flow.
Who MetaVia Inc competes with
P/S Multiple biogen.com (BIIB)|Neurocrine Biosciences, Inc. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio RGC|Axsome Therapeutics Inc - P/S Multiple|Price-to-Revenue Coefficient ACADIA Corp ACAD|Xenon Pharmaceuticals (XENE) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio VKTX|SUPN (Supernus) - P/S Multiple|Market Cap to Revenue Catalyst Pharma (CPRX)|Price-to-Revenue Ratio Denali Therapeutics Inc (DNLI)|Market Cap to Revenue Harmony Corp HRMY|Biohaven Ltd. - Market Cap to Revenue|Market Cap to Sales Volume AMLX (amylyx.com)|TRVI: Market Cap to Revenue|PRAX: Price-to-Revenue Ratio|AVXL: P/S Multiple|CeriBell EEG (CBLL) - P/S Multiple|Price-to-Revenue Ratio Prothena Biosciences|Market Cap to Revenue Ratio ALEC (Alector Therapeutics)|P/S Multiple ANNX|OMER - Price to Sales|Neurogene Corp - Market Cap to Revenue|P/S Multiple AC Immune Inc ACIU|VYGR - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio NMRA (neumoratx.com)|Scilex (SCLX) - Price-to-Revenue Ratio|Price to Sales Tevogen Bio Holdings Inc. (TVGN)|Price-to-Revenue Ratio Alpha Cognition Inc|Market Cap to Revenue Cognition Therapeutics Inc. (CGTX)|P/S Multiple IKT|SAVA - Price to Sales|Assertio - Market Cap to Revenue|Market Cap to Sales Volume COYA (Coya Therapeutics Inc)|VistaGen Therapeutics Inc - P/S Multiple|OVID - P/S Multiple|ABOS (Acumen Pharmaceuticals) - Market Cap to Revenue|CRVO (cervomed.com) - Price-to-Revenue Ratio|ATHE (Alterity Therapeutics Ltd.) - P/S Multiple|Clene Nanomedicine (CLNN) - Price-to-Revenue Coefficient|P/S Multiple PEPG|P/S Multiple Jupiter Neurosciences, Inc. (JUNS)|Relmada Therapeutics - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ANVS|Grace Tx - P/S Multiple|Price-to-Revenue Coefficient Firefly Neuroscience, Inc. AIFF|anewmeds.com (KLTO) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio NRSN|RVPH (Reviva Pharmaceuticals) - P/S Multiple|Market Cap to Revenue neuraxis.com (NRXS)|Price-to-Revenue Ratio Helius Medical (HSDT)|Market Cap to Revenue passagebio.com PASG|Neuphoria Therapeutics - Market Cap to Revenue|Market Cap to Sales Volume NERV (Minerva)|ATHA: Market Cap to Revenue|ADXN: Price-to-Revenue Ratio|ALZN: P/S Multiple|Cyclerion Therapeutics, Inc. (CYCN) - P/S Multiple|Price-to-Revenue Ratio Protagenic Therapeutics Inc.|Market Cap to Revenue Ratio KTTA (Pasithea)|P/S Multiple CRGT|ATXI - Price to Sales|BrainStorm Cell Therapeutics - Market Cap to Revenue|P/S Multiple Cara Therapeutics Inc. CARA|CHRO - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio ELYM (Eliem Therapeutics)|intracellulartherapies.com (ITCI) - Price-to-Revenue Ratio|Price to Sales longboardpharma.com (LBPH)|Price-to-Revenue Ratio Marinus Pharmaceuticals, Inc.|Market Cap to Revenue NKGen Biotech Inc (NKGN)|P/S Multiple NRBO|SAGE - Price to Sales|Synaptogenix, Inc. - Market Cap to Revenue|Market Cap to Sales Volume TRVN (trevena.com)|Vigil Neuro - P/S Multiple|WENA - P/S Multiple|CERE (Cerevel) - Market Cap to Revenue
